A team of Greenberg Traurig attorneys recently represented Intec Pharma Ltd. (NASDAQ and TASE: NTEC) on the closing of its offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the underwriters of their over-allotment option in the amount of … Continue Reading